IP Library Granted Patent US 11,872,219
Granted Patent B2
US 11,872,219 · App. 17/327,888 · Granted Jan 16, 2024

Compositions and methods for intrathecal administration of MCOPPB for pain relief

Inventors: James N. Campbell (Baltimore, MD); Barton Harley Manning (Arlington, TX)
Assignee: Centrexion Therapeutics Corporation
A61K31/4545A61K9/0019A61P23/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,872,219
App. No.
17/327,888
Granted
Jan 16, 2024
Kind
B2
Abstract

The invention provides compositions and methods for intrathecal administration of the compound MCOPPB or a pharmaceutically acceptable salt thereof for treating pain, such as neuropathic pain suffered by an adult human.

Claims (34)

1. A method of treating a human patient suffering from pain, comprising intrathecally administering to a human patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising (i) MCOPPB or a pharmaceutically acceptable salt thereof and (ii) a pharmaceutically acceptable carrier, to thereby treat the pain, wherein the administering delivers a daily dose of MCOPPB in the range of about 0.1 μg to 10 μg.

2. The method of claim 1 , wherein the pain is neuropathic pain.

3. The method of claim 1 , wherein the pain is inflammatory pain.

4. The method of claim 1 , wherein the pain is arthritis pain.

5. The method of claim 1 , wherein the pain is arthritis pain selected from osteoarthritis pain and rheumatoid arthritis pain.

6. The method of claim 1 , wherein the pain is due to cancer.

7. The method of claim 1 , wherein the pain is due to a cancer selected from the group consisting of a solid tumor, leukemia, and lymphoma.

8. The method of claim 1 , wherein the pain is due to a cancer selected from the group consisting of a bladder cancer, breast cancer, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, esophageal cancer, leukemia, lung cancer, liver cancer, skin cancer, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal cancer, stomach cancer, testicular cancer, and uterine cancer.

9. The method of claim 1 , wherein the pain is complex regional pain syndrome.

10. The method of claim 9 , wherein the complex regional pain syndrome is reflex sympathetic dystrophy pain.

11. The method of claim 1 , wherein the pain is located in the patient's hand, wrist, arm, shoulder, back, leg, knee, ankle, foot, or toe.

12. The method of claim 1 , wherein the pain is low back pain.

13. The method of claim 1 , wherein the pain is chronic low back pain.

14. The method of claim 12 , wherein the method is characterized by achieving at least a 40% reduction in pain intensity relative to pain observed without administering said pharmaceutical composition.

15. The method of claim 12 , wherein the method is characterized by achieving at least a 60% reduction in pain intensity relative to pain observed without administering said pharmaceutical composition.

16. The method of claim 12 , wherein the method is characterized by achieving at least an 80% reduction in pain intensity relative to pain observed without administering said pharmaceutical composition.

17. The method of claim 12 , wherein the administering delivers a daily dose of MCOPPB in the range of about 0.5 μg to 1 μg.

18. The method of claim 12 , wherein the administering delivers a daily dose of MCOPPB in the range of about 1 μg to 2 μg.

19. The method of claim 12 , wherein the administering delivers a daily dose of MCOPPB in the range of about 2 μg to 3 μg.

20. The method of claim 12 , wherein the administering delivers a daily dose of MCOPPB in the range of about 3 μg to 4 μg.

21. The method of claim 12 , wherein the administering delivers a daily dose of MCOPPB in the range of about 4 μg to 5 μg.

22. The method of claim 12 , wherein the administering delivers a daily dose of MCOPPB in the range of about 5 μg to 6 μg.

23. The method of claim 12 , wherein the administering delivers a daily dose of MCOPPB in the range of about 6 μg to 7 μg.

24. The method of claim 12 , wherein the administering delivers a daily dose of MCOPPB in the range of about 7 μg to 8 μg.

25. The method of claim 12 , wherein the administering delivers a daily dose of MCOPPB in the range of about 8 μg to 9 μg.

26. The method of claim 12 , wherein the administering delivers a daily dose of MCOPPB in the range of about 9 μg to 10 μg.

27. A method of treating a human patient suffering from pain, comprising intrathecally administering to a human patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising (i) MCOPPB or a pharmaceutically acceptable salt thereof and (ii) a pharmaceutically acceptable carrier, to thereby treat the pain, wherein the administering delivers a daily dose of MCOPPB in the range of about 10 μg to 50 μg.

28. The method of claim 27 , wherein the pain is neuropathic pain.

29. The method of claim 27 , wherein the pain is inflammatory pain.

30. The method of claim 27 , wherein the pain is low back pain.

31. The method of claim 30 , wherein the administering delivers a daily dose of MCOPPB in the range of about 10 μg to 20 μg.

32. The method of claim 30 , wherein the administering delivers a daily dose of MCOPPB in the range of about 20 μg to 30 μg.

33. The method of claim 30 , wherein the administering delivers a daily dose of MCOPPB in the range of about 30 μg to 40 μg.

34. The method of claim 30 , wherein the administering delivers a daily dose of MCOPPB in the range of about 40 μg to 50 μg.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Nov 21, 2025
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT
To: CENTREXION THERAPEUTICS CORPORATION
Reel/Frame 073683/0099 →
SECURITY INTEREST Recorded Nov 21, 2025
From: CENTREXION THERAPEUTICS CORPORATION
To: ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 073683/0108 →
SECURITY INTEREST Recorded Jul 12, 2023
From: CENTREXION THERAPEUTICS CORPORATION
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT
Reel/Frame 064256/0125 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2021
From: CAMPBELL, JAMES N.
To: CENTREXION THERAPEUTICS CORPORATION
Reel/Frame 056345/0268 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 25, 2021
From: MANNING, BARTON HARLEY
To: CENTREXION THERAPEUTICS CORPORATION
Reel/Frame 056345/0291 →
Continuity (3)
Continuation 16589218 · Oct 1, 2019
Provisional Application 62739393 · Oct 1, 2018
Related Publication 20210386728A1 · Dec 16, 2021